牛牛AI助理已提取核心訊息
On January 16, 2024, Marpai Inc., a health technology company, announced the entry into a Securities Purchase Agreement with key insiders, including entities controlled by CEO Damien Lamendola, Chairman Yaron Eitan, and director Robert Pons. The agreement involves the private placement sale of 1,322,100 shares of Marpai's Class A common stock at a price of $0.9201 per share, equivalent to the consolidated closing bid price on Nasdaq for that date. The transaction is exempt from registration under the Securities Act of 1933, according to Section 4(a)(2) and Rule 506(b) of Regulation D, meaning the shares cannot be sold in the U.S. without registration or an exemption. The details of the Securities Purchase Agreement are disclosed in the company's Form 8-K filed with the SEC and are further detailed in Exhibit 10.1 attached to the report.
On January 16, 2024, Marpai Inc., a health technology company, announced the entry into a Securities Purchase Agreement with key insiders, including entities controlled by CEO Damien Lamendola, Chairman Yaron Eitan, and director Robert Pons. The agreement involves the private placement sale of 1,322,100 shares of Marpai's Class A common stock at a price of $0.9201 per share, equivalent to the consolidated closing bid price on Nasdaq for that date. The transaction is exempt from registration under the Securities Act of 1933, according to Section 4(a)(2) and Rule 506(b) of Regulation D, meaning the shares cannot be sold in the U.S. without registration or an exemption. The details of the Securities Purchase Agreement are disclosed in the company's Form 8-K filed with the SEC and are further detailed in Exhibit 10.1 attached to the report.
2024年1月16日，健康科技公司Marpai Inc. 宣佈與包括首席執行官達米安·拉門多拉、董事長亞倫·艾坦和董事羅伯特·龐斯控制的實體在內的主要內部人士簽訂證券購買協議。該協議涉及以每股0.9201美元的價格私募出售1,322,100股Marpai的A類普通股，相當於當日納斯達克的合併收盤價。根據D條例第4（a）（2）條和第506（b）條，根據1933年《證券法》，該交易免於註冊，這意味着未經註冊或豁免，不得在美國出售股票。證券購買協議的細節在公司向美國證券交易委員會提交的8-K表格中披露，並在報告所附的附錄10.1中進一步詳細說明。
2024年1月16日，健康科技公司Marpai Inc. 宣佈與包括首席執行官達米安·拉門多拉、董事長亞倫·艾坦和董事羅伯特·龐斯控制的實體在內的主要內部人士簽訂證券購買協議。該協議涉及以每股0.9201美元的價格私募出售1,322,100股Marpai的A類普通股，相當於當日納斯達克的合併收盤價。根據D條例第4（a）（2）條和第506（b）條，根據1933年《證券法》，該交易免於註冊，這意味着未經註冊或豁免，不得在美國出售股票。證券購買協議的細節在公司向美國證券交易委員會提交的8-K表格中披露，並在報告所附的附錄10.1中進一步詳細說明。
有用
沒用